Introduction
Most roles in regulatory affairs carry professional responsibility without carrying personal legal liability for a specific decision. The EU Qualified Person, almost always shortened to QP, is the exception. A QP is a named individual, registered against a specific manufacturing or importation authorisation, who personally certifies that each batch of a medicinal product has been manufactured and tested in accordance with EU Good Manufacturing Practice and the terms of its marketing authorisation before that batch can be released to the European market. That certification is not a formality routed through a quality system; it is a decision one person signs their name to, with real regulatory and legal consequences attached to getting it wrong.
Because the role sits at the intersection of quality assurance, GMP compliance, and regulatory interpretation, it's often poorly understood outside the people who hold it or report into one. Understanding what a QP actually does day to day is useful both for anyone considering the route into the role and for regulatory affairs professionals who work alongside QPs constantly without ever having done the job themselves.
The Legal Basis for the Role
The QP role exists because EU pharmaceutical legislation, principally Directive 2001/83/EC for medicinal products for human use and the parallel veterinary directive, requires every manufacturing authorisation holder to have at least one Qualified Person permanently and continuously at its disposal. That QP must be named on the site's manufacturing or importation authorisation and registered with the relevant national competent authority. Annex 16 of the EU GMP guidelines sets out in detail what batch certification actually requires: confirmation that the batch was produced in accordance with GMP, that it complies with the marketing authorisation, and, for products manufactured or imported from outside the EU, that appropriate testing and assessment of the manufacturing conditions has taken place.
This is a fundamentally different kind of accountability than most regulatory affairs roles carry. A regulatory affairs lead can get a submission strategy wrong and the consequence is a rejected variation or a delayed approval. A QP who certifies a batch that shouldn't have been released is personally answerable to the competent authority, and in some member states can face direct regulatory or even criminal sanction. That weight shapes everything about how the role is structured and who is allowed to hold it.
What the Job Actually Looks Like Day to Day
The core activity is batch certification: reviewing a batch's manufacturing and testing records, any deviations or out-of-specification results raised during production, and the supporting documentation, then deciding whether the batch meets the standard required to be released. In practice this means the QP is reading quality investigations closely enough to form an independent judgment, not simply countersigning a QA sign-off that's already been made elsewhere. A QP who treats certification as a rubber stamp is not doing the job as the legislation intends it, and inspectors assess exactly this when they review a site's QP arrangements.
Beyond individual batch decisions, QPs are typically deeply involved in the quality systems that feed into those decisions: change control, deviation and CAPA review, supplier and contract manufacturer qualification, and the ongoing assessment of whether a site's GMP compliance status supports continued certification. Many QPs also sit on or chair the quality review boards that assess trends across multiple batches, because a pattern of recurring minor deviations is often more informative than any single batch's record in isolation.
For products manufactured outside the EU, the QP's role extends to assessing the exporting site's manufacturing and quality arrangements, often informed by audits, to decide whether a reduced testing regime at the EU import site is justified or whether full re-testing is required. This is where the role overlaps most directly with supply chain and external manufacturing oversight, and it's a significant part of the workload for QPs working at sites that rely heavily on contract manufacturing organisations or import drug substance and finished product from third countries.
Where the QP Role Meets Regulatory Affairs
A batch can only be certified against what the marketing authorisation actually says, which means a QP has to understand the approved specifications, manufacturing process description, and any post-approval commitments as well as a regulatory affairs professional does, sometimes better. In practice this creates constant, close collaboration with regulatory affairs around managing variations: a QP cannot certify a batch against a process or specification that hasn't been formally approved, so the timing of post-approval change implementation has to be tightly coordinated between the two functions. A regulatory team that implements a manufacturing change before the corresponding variation has actually been approved creates a genuine problem for the QP, not a paperwork inconvenience.
This is also where the distinction between the two functions is clearest. Regulatory affairs is primarily about building and defending the case that a product and its manufacturing meet the requirements set out in the dossier; the QP role is about independently verifying, batch by batch, that what was actually produced matches that case closely enough to release. The two functions need each other constantly and neither can substitute for the other.
Becoming Eligible: The Route In
EU legislation sets minimum requirements for QP eligibility: a relevant degree, generally in pharmacy, chemistry, pharmaceutical chemistry and technology, biology, or a related scientific discipline, combined with a period of practical experience in activities such as qualitative and quantitative analysis of medicinal products, quality assurance, and manufacturing-related testing. Member states implement the specifics of the eligibility assessment differently, and in several countries, including the historically well-trodden UK and Irish route, professional bodies run a formal QP eligibility assessment process rather than treating a degree and years of experience as automatically sufficient.
In practice, most people become eligible after several years working in quality assurance or quality control roles, often starting as a QP designate under the mentorship of an already-registered QP at the same site, gradually taking on more of the certification review and decision-making before formally qualifying. This apprenticeship period matters more than the formal eligibility assessment itself; reviewing documentation on paper is a different skill from forming an independent judgment under time pressure when a batch's investigation doesn't close out as cleanly as everyone involved was hoping.
QP vs. Responsible Person: Two Distinct Roles
The QP is sometimes confused with the Responsible Person, or RP, required under EU wholesale distribution rules, and the two get mixed up often enough to be worth untangling. The RP oversees that a wholesale distribution authorisation holder's distribution activities, such as storage, transport, and supply chain integrity, comply with Good Distribution Practice. The QP's authority is manufacturing-side: certifying that a batch was produced and tested to the required standard before it can be released at all. A product generally passes through QP certification first and GDP-compliant distribution afterward, and while the same person occasionally holds both registrations at a smaller company, they're legally and functionally separate responsibilities with separate competency requirements. Getting this distinction right matters in practice because the two roles show up on different authorisations and are assessed separately at inspection.
Inspections and the QP's Standing With Regulators
When a competent authority inspects a manufacturing site, the QP arrangements are a standing area of inspection focus, not a peripheral check. Inspectors look at whether the QP genuinely has the authority, time, and independence to exercise the judgment the role requires, rather than being structurally pressured by commercial deadlines to certify batches faster than a proper review supports. A QP who reports into a commercial or operations function, rather than having a reporting line that protects their independence on release decisions, is a recurring inspection finding at sites that haven't thought carefully about how the role is organised. This is also why experienced QPs tend to be closely involved in how their own role is positioned within a company's organisational structure, not just in the certification decisions themselves.
Demand and Where QPs Are Needed
A few structural trends have kept QP demand elevated. The growth of biologics, cell and gene therapies, and other advanced therapy medicinal products has created a need for QPs with specific experience certifying these more complex product types, where manufacturing and testing are often less standardised than for conventional small-molecule drugs, and where short product shelf lives for some cell therapies compress the time available for a thorough review even further. The continued growth of contract development and manufacturing organisations means more sites need their own QP capability rather than relying on a sponsor's QP, since certification has to happen at the site actually responsible for release. And the UK's departure from the EU single market created a lasting structural need for separate UK-registered and EU-registered QP arrangements at companies supplying both markets, rather than one QP covering both, which widened the pool of sites actively recruiting for the role.
For people building a career toward this role, the practical path is to get into quality assurance or quality control work that involves real exposure to batch disposition decisions and deviation investigations, build that experience at a site handling product types you want to specialise in, and find a QP willing to mentor you through the designate period. It's a slower route into a senior role than many regulatory affairs career paths, but it leads to one of the few positions in the industry with genuinely irreplaceable, personally accountable decision-making authority, and QPs with experience in advanced therapies or complex biologics are in a particularly strong position given how few people currently hold that combination.
Conclusion
The QP role is often described from the outside as a quality function, and it is, but it's also one of the clearest points where regulatory compliance becomes a specific, personally accountable decision rather than an organisational process. For anyone weighing whether to pursue it, the honest framing is that it trades a longer, more structured path to qualification for a role with real, individual decision-making weight that few other positions in the industry carry. For regulatory affairs professionals who work alongside QPs without holding the role themselves, understanding how closely certification depends on exactly what's been approved in the marketing authorisation explains why QPs are often the most insistent voice in the room about getting variation timing right.